naringenin and Cardiovascular Diseases

naringenin has been researched along with Cardiovascular Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Hosseinzadeh-Attar, MJ; Mansouri, S; Naeini, F; Namkhah, Z; Rezayat, SM; Tutunchi, H; Yaseri, M	1
Farzaei, MH; Heidary Moghaddam, R; Little, PJ; Moradi, SZ; Samimi, Z; Xu, S	1
Chatziathanasiadou, MV; Deligianni, M; Kellici, TF; Kostagianni, AD; Stylos, E; Tselepis, AD; Tsiailanis, A; Tsoumani, M; Tzakos, AG	1

Reviews

1 review(s) available for naringenin and Cardiovascular Diseases

Article	Year
Naringenin and naringin in cardiovascular disease prevention: A preclinical review. European journal of pharmacology, 2020, Nov-15, Volume: 887 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cardiotonic Agents; Cardiovascular Diseases; Flavanones; Humans	2020

Trials

1 trial(s) available for naringenin and Cardiovascular Diseases

Article	Year
Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial. European journal of gastroenterology & hepatology, 2022, 03-01, Volume: 34, Issue:3 Topics: Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; Flavanones; Heart Disease Risk Factors; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Risk Factors	2022

Article

Year

Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.

European journal of gastroenterology & hepatology, 2022, 03-01, Volume: 34, Issue:3

Topics: Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; Flavanones; Heart Disease Risk Factors; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Risk Factors

2022

Other Studies

1 other study(ies) available for naringenin and Cardiovascular Diseases

Article	Year
Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. Biochimica et biophysica acta. General subjects, 2017, Volume: 1861, Issue:11 Pt A Topics: Aspirin; Cardiovascular Diseases; Computer Simulation; Cyclooxygenase 1; Docosahexaenoic Acids; Flavanones; Flavonoids; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, PAR-1; Receptors, Purinergic P2Y12; Signal Transduction; Standard of Care; Tandem Mass Spectrometry	2017

Article

Year

Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.

Biochimica et biophysica acta. General subjects, 2017, Volume: 1861, Issue:11 Pt A

Topics: Aspirin; Cardiovascular Diseases; Computer Simulation; Cyclooxygenase 1; Docosahexaenoic Acids; Flavanones; Flavonoids; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, PAR-1; Receptors, Purinergic P2Y12; Signal Transduction; Standard of Care; Tandem Mass Spectrometry

2017